A Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis. The gene discussed is CD19; the disease is multiple sclerosis.